U.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warns

Dr. Reddy's Laboratories (RDY) CEO Erez Israeli warned that President Donald Trump's proposed tariffs on generic drugs will drive up prices for U.S. patients, presenting a direct cost threat to one of the largest suppliers of generics to the American market. The India-based drugmaker ships a significant portion of its product portfolio to the United States, making tariff policy a material risk to both margins and market share.

Trump's tariff proposals targeting pharmaceutical imports would mark a sharp policy shift for an industry that has long relied on offshore manufacturing to keep generic prices low. Dr. Reddy's, along with other Indian pharma exporters, has built its U.S. business on cost arbitrage; new duties would compress that advantage and force the company to either absorb the hit or pass costs to distributors and consumers.

Israeli's public pushback signals the industry is mobilizing against the policy before implementation. The timing matters: generic drug pricing has been a political flashpoint, and higher costs could trigger regulatory backlash or accelerate domestic manufacturing incentives that further squeeze foreign suppliers.